Corrigendum to: High Body Mass Index is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection (Tohoku J. Exp. Med., 253, 85-94, 2021, 10.1620/tjem.253.85)

Toyotaka Kasai, Sho Suzuki, Chika Kusano, Hisatomo Ikehara, Ryoji Ichijima, Motoki Ohyauchi, Masashi Kawamura, Yoshioki Yoda, Moriyasu Nakahara, Koichi Kawabe, Takuji Gotoda

Research output: Contribution to journalComment/debate

Abstract

In the version of this article published in the February issue, 2021, the author mistook the affiliation of the first author. The correct affiliation of Toyotaka Kasai is Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan and Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. Concerning the “Table 1” (Page 91) of this article, the authors found that the sex item was missing. Table 1 added sex item is the next page. The authors sincerely apologize for the oversight on this matter.

Original languageEnglish
Pages (from-to)173-174
Number of pages2
JournalTohoku Journal of Experimental Medicine
Volume259
Issue number2
DOIs
Publication statusPublished - Feb 2023

Fingerprint

Dive into the research topics of 'Corrigendum to: High Body Mass Index is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection (Tohoku J. Exp. Med., 253, 85-94, 2021, 10.1620/tjem.253.85)'. Together they form a unique fingerprint.

Cite this